MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

Search

Crinetics Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

32.44 10.64

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

29.1

Massimo

32.47

Metriche Chiave

By Trading Economics

Entrata

-16M

-97M

Vendite

361K

361K

Margine di Profitto

-26,807.202

Dipendenti

437

EBITDA

-17M

-110M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+163.02% upside

Dividendi

By Dow Jones

Utili prossimi

7 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-369M

2.8B

Apertura precedente

21.8

Chiusura precedente

32.44

Notizie sul Sentiment di mercato

By Acuity

50%

50%

157 / 376 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

9 lug 2025, 15:46 UTC

I principali Market Mover

BitMine Shares Fall After Closing of $250 Million Private Placement

9 lug 2025, 23:44 UTC

Discorsi di Mercato

Gold Edges Higher Amid U.S. Tariff Concerns -- Market Talk

9 lug 2025, 23:42 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

9 lug 2025, 23:42 UTC

Discorsi di Mercato

Nikkei May Trade Rangebound as U.S. Tariff Uncertainty Continues -- Market Talk

9 lug 2025, 22:59 UTC

Discorsi di Mercato

Reliance Worldwide's Costs at Risk From Copper Tariffs -- Market Talk

9 lug 2025, 22:59 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

9 lug 2025, 20:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Health Care Roundup: Market Talk

9 lug 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

9 lug 2025, 20:26 UTC

Utili

Nvidia Is the Most Valuable Company Ever. Why $5 Trillion Could Be Next. -- Barrons.com

9 lug 2025, 19:18 UTC

Discorsi di Mercato

Oil Futures End Little Changed After Big U.S. Crude Stock Build -- Market Talk

9 lug 2025, 19:03 UTC

Discorsi di Mercato

U.S. Natural Gas Posts Back-to-Back Losses -- Market Talk

9 lug 2025, 18:31 UTC

Discorsi di Mercato

Some Fed Officials Supported Considering July Cut -- Market Talk

9 lug 2025, 17:07 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Honeywell's Streamlining Efforts Clear Path for Stock to Catch Up -- Market Talk

9 lug 2025, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk -2-

9 lug 2025, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

9 lug 2025, 16:20 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Health Care Roundup: Market Talk

9 lug 2025, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

9 lug 2025, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

9 lug 2025, 16:14 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

9 lug 2025, 16:14 UTC

Discorsi di Mercato

Rents in Canada Soften For Ninth-Straight Month -- Market Talk

9 lug 2025, 16:14 UTC

Acquisizioni, Fusioni, Takeovers

Apple Has Dropped the Ball on AI. Buying Perplexity Could Help It Catch Up, Say Analysts. -- Barrons.com

9 lug 2025, 16:12 UTC

Discorsi di Mercato

Gold Futures Broadly Flat in Largely Directionless Trade -- Market Talk

9 lug 2025, 16:08 UTC

Discorsi di Mercato

Oil Ticks Higher Amid Large U.S. Crude Build, Red Sea Tensions, Tariff Uncertainty -- Market Talk

9 lug 2025, 15:31 UTC

I principali Market Mover

BitMine Shares Fall After Closing of $250M Private Placement

9 lug 2025, 15:31 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

With Competing Bids Unlikely, Merck's Path to Acquiring Verona Looks Smooth -- Market Talk

9 lug 2025, 15:27 UTC

Discorsi di Mercato

Copper Rally Expected to Fade Amid Tepid Global Demand -- Market Talk

9 lug 2025, 14:36 UTC

Acquisizioni, Fusioni, Takeovers

Merck to Buy Verona Pharma in $10 Billion Deal -- 2nd Update

9 lug 2025, 14:31 UTC

Acquisizioni, Fusioni, Takeovers

Meta Has Surged on the Back of AI Software. Why Hardware Is the Next Play. -- Barrons.com

9 lug 2025, 14:26 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

9 lug 2025, 14:26 UTC

Discorsi di Mercato

Aug 1 Tariffs Will Boost Average Rate Near 15%, JPMorgan Estimates -- Market Talk

Confronto tra pari

Modifica del prezzo

Crinetics Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

163.02% in crescita

Previsioni per 12 mesi

Media 77.25 USD  163.02%

Alto 97 USD

Basso 60 USD

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

9 ratings

9

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

30.39 / 33.46Supporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Neutral Evidence

Sentiment

By Acuity

157 / 376 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.